Basilea provides corporate update: Key oncology clinical studies with derazantinib and lisavanbulin remain on track
» Report
Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.
Anmelden oder
Jetzt abonnieren!
Archiv: Alle Kategorien
Basilea gibt Unternehmens-Update
» Report
Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe
» Report
L'Helvetia Venture Fund investit dans la TrustTech suisse Skribble
» Report
Implenia et Ina Invest annoncent les termes d'une offre de souscription d'approximativement CHF 100 millions
» Report
Cassiopea Announces Results for First Quarter 2020
» Report
Helvetia Venture Fund invests in Swiss TrustTech company Skribble
» Report
Implenia and Ina Invest announce terms of rights offering of approximately CHF 100 million
» Report
Landis+Gyr publishes Annual Report 20 19 and Invitation to AGM 20 20
» Report
Cassiopea gibt Resultate für das 1. Quartal 2020 bekannt
» Report
Helvetia Venture Fund investiert in Schweizer TrustTech Skribble
» Report
Implenia und Ina Invest geben die Bedingungen der Bezugsrechtsemission von ungefähr CHF 100 Millionen bekannt
» Report
Landis+Gyr veröffentlicht Geschäftsbericht 2019 und Einladung zur Generalversammlung 2020
» Report
Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
» Report
WISeKey is Adapting its R&D and Extended Patents Portfolio to the Post-COVID 19 Economy with Specific Focus on Post-Quantum Cryptography
» Report
Givaudan to acquire Alderys: Strengthening our expertise in sustainable disruptive biotechnology processes
» Report
Logitech - Logitech Announces New Share Buyback Program And Proposed FY20 Dividend
» Report
US State of Maryland Expands Flame Retardant Law
» Report
SGS Expands Network of ISTA Labs and Adds ISTA’s 6-Amazon Certification Testing
» Report
CEN Publishes Amendment 3 to EN 71-7 ‘Finger Paints’
» Report
